Novel Targeted Agents in Combination with R-MINE (RMINE+X) Based on Different Molecular Subtypes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma：a Phase 2 Multicenter Study
Jinhua Liang(Jiangsu Province Hospital), Wei Xu(Jiangsu Province Hospital), Lintao Bi(First Bethune Hospital of Jilin University), Yue Li(Southwest Petroleum University), Jianyong Li(Jiangsu Province Hospital), Hua Yin(Jiangsu Province Hospital), Weiwei Qin(Nanjing University of Science and Technology), Jia‐Zhu Wu(Augusta University Health), Li Wang(University of Science and Technology of China), Hao-Rui Shen(Nanjing Medical University)
Cited by 2
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
|Frontiers in Immunology|2017|296
Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma
|Cancer Cell|2020|238
Circular RNA circRNA_15698 aggravates the extracellular matrix of diabetic nephropathy mesangial cells via miR‐185/TGF‐β1
|Journal of Cellular Physiology|2018|172